The oestrogen-like effect of 4-hydroxytamoxifen on induction of transforming growth factor alpha mRNA in MDA-MB-231 breast cancer cells stably expressing the oestrogen receptor

British Journal of Cancer

Volumn 77, Issue 11, 1998, Pages 1812-1819

  Levenson, A S ^a   Tonetti, D A ^a   Jordan, V C ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

4 Hydroxytamoxifen; Breast cancer; ICI 182,780; Oestrogen receptor; TGF gene

Indexed keywords

4 HYDROXYTAMOXIFEN; ANTIESTROGEN; DNA; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; FULVESTRANT; LUCIFERASE; MESSENGER RNA; MUTANT PROTEIN; TRANSFORMING GROWTH FACTOR ALPHA;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CONTROLLED STUDY; DNA TRANSFECTION; ESTROGEN ACTIVITY; GENE INDUCTION; HORMONE RESPONSIVE ELEMENT; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DNA BINDING; REPORTER GENE; TRANSCRIPTION REGULATION;

EID: 0031779534     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.301     Document Type: Article

References (56)

1. Albert JL, Sundstrom SA and Lyttle CR (1990) Estrogen regulation of placental alkaline phosphatase gene expression in a human endometrial adenocarcinoma cell line. Cancer Res 50: 3306-3310
2. Astruc ME, Chabret C, Bali P, Gagne D and Pons M (1995) Prolonged treatment of breast cancer cells with antiestrogens increases the activating protein-1-mediated response: involvement of the estrogen receptor. Endocrinology 136: 824-832
3. Bates SE, Davidson NE, Valverius EM, Freter CE, Dickson RB, Tam JP, Kudlow JE, Lippman ME and Salomon DS (1988) Expression of transforming growth factor α and its messenger ribonucleic acid in breast cancer: its regulation by estrogen and its possible functional significance. Mol Endocrinol 2: 543-555
4. Butler WB, Berlinski PJ, Hillman RM, Kelsey WH and Toenniges MM (1986) Relation of in vitro properties to tumorigenicity for a series of sublines of the human breast cancer cell line MCF-7. Cancer Res 46: 6339-6348
5. Campbell ML (1995) Lipofection reagents prepared by a simple ethanol injection technique. Bio Techniques 18: 1027-1032
6. Catherino WH and Jordan VC (1995) Increasing the number of tandem estrogen response elements increases the estrogenic activity of a tamoxifen analogue. Cancer Lett 92: 39-47
7. Catherino WH, Wolf DM and Jordan VC (1995) A naturally occurring estrogen receptor mutation results in increased estrogenicity of a tamoxifen analog. Mol Endocrinol 9: 1053-1063
8. Dauvois S, Danielian PS, White R and Parker MG (1992) The antiestrogen ICI 164, 384 reduces cellular estrogen receptor content by increasing its turnover. Proc Natl Acad Sci USA 89: 4037-4041
9. Dauvois S, White R and Parker MG (1993) The antiestrogen ICI 182,780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci 106: 1377-1388
10. Dickson RB, Johnson MD, Bano M, Shi E, Kurebayashi J, Ziff B, Martinez-Lacaci I, Amundadottir LT and Lippman ME (1992) Growth factors in breast cancer: mitogenesis to transformation. J Steroid Biochem Mol Biol 43: 69-78
11. Early Breast Cancer Trialists' Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339: 1-15; 71-85
12. El-Ashry D, Chrysogelos SA, Lippman ME and Kern FG (1996) Estrogen induction of TGF-α is mediated by an estrogen response element composed of two imperfect palindromes. J Steroid Biochem Mol Biol 59: 261-269
13. Furr BJA and Jordan VC (1984) The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 25: 127-205
14. Gaub MP, Bellard M, Scheuer I, Chambon P and Sassone CP (1990) Activation of the ovalbumin gene by the estrogen receptor involves the fos-jun complex. Cell 63: 1267-1276
15. Gibson MK, Nemmers LA, Beckman Jr WC, Davis VL, Curtis SW and Korach KS (1991) The mechanism of ICI 164,384 antiestrogenicity involves rapid loss of estrogen receptor in uterine tissue. Endocrinology 129: 2000-2010
16. Gong Y, Ballejo G, Murphy LC and Murphy LJ (1992) Differential effects of estrogen and antiestrogens on transforming growth factor gene expression in endometrial adenocarcinoma cells. Cancer Res 52: 1704-1709
17. Gottardis MM, Robinson SP, Satyaswaroop PG and Jordan VC (1988) Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res 48: 812-815
18. Halachmi S, Marden E, Martin G, MacKay H, Abbondanza C and Brown M (1994) Estrogen receptor-associated proteins: possible mediators of hormone-induced transcription. Science 264: 1455-1457
19. Huynh HT and Pollak M (1993) Insulin-like growth factor-I gene expression in the uterus is stimulated by tamoxifen and inhibited by the pure antiestrogen ICI 182,780. Cancer Res 53: 5585-5588
20. Jamil A, Croxtall JD and White JO (1991) The effect of antiestrogens on cell growth and progesterone receptor concentration in human endometrial cancer cells (Ishikawa). Mol Endocrinol 6: 215-221
21. Jeng MH, Jiang SY and Jordan VC (1994) Paradoxical regulation of estrogen-dependent growth factor gene expression in estrogen receptor (ER)-negative human breast cancer cells stably expressing ER. Cancer Lett 82: 123-128
22. Jiang SY and Jordan VC (1992) Growth regulation of estrogen receptor negative breast cancer cells transfected with complementary DNAs for estrogen receptor. J Natl Cancer Inst 84: 580-591
23. Jordan VC (1996) Tamoxifen: A Guide for Clinicians and Patients. PRR: Huntington, New York
24. Jordan VC, Collins MM, Rowsby L and Prestwich G (1977) A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J Endocrinol 75: 305-316
25. Jordan VC, Phelps E and Lindgren JU (1987) Effect of antiestrogens on bone in castrated and intact female rats. Breast Cancer Res Treat 10: 31-35
26. Levenson AS and Jordan VC (1994) Transfection of human estrogen receptor (ER) cDNA into ER-negative mammalian cell lines. J Steroid Biochem Mol Biol 51: 229-239
27. Levenson AS, Catherino WH and Jordan VC (1997) Estrogenic activity is increased for an antiestrogen by a natural mutation of the estrogen receptor. J Steroid Biochem Mol Biol 60: 261-268
28. Lippman ME and Dickson RB (1989) Mechanisms of growth control in normal and malignant breast epithelium. Recent Prog Horm Res 45: 383-440
29. Lippman ME, Bolan G and Huff K (1976) The effects of estrogens and antiestrogens on hormone responsive human breast cancer in long-term tissue culture. Cancer Res 36: 4595-4601
30. Love RR, Wiebe DA, Newcomb PA, Cameron L, Leventhal H, Jordan VC, Feyzi J and DeMets DL ( 1991 ) Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med 115: 860-864
31. Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC, Carbone PP and DeMets DL (1992) Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326: 852-856
32. Luyten GPM, Hoogeveen AT and Galjaard H (1988) A fluorescence staining method for the demonstration and measurement of lysosomal enzyme activities in single cells. J Histochem Cytochem 33: 965
33. Mahfoudi A, Roulet E, Dauvois S, Parker MG and Wahli W (1995) Specific mutations in the estrogen receptor change the properties of an antiestrogen to full agonists. Proc Natl Acad Sci USA 92: 4206-4210
34. Montano MM, Ekena K, Krueger KD, Keller AL and Katzenellenbogen BS (1996) Human estrogen receptor ligand activity inversion mutants: receptors that interpret antiestrogens as estrogens and estrogens as antiestrogens and discriminate among different antiestrogens. Mol Endocrinol 10: 230-242
35. Murphy LC and Dotzlaw H (1989) Regulation of transforming growth factor α and transforming growth factor β messenger ribonucleic acid abundance in T-47D human breast cancer cells. Mol Endocrinol 3: 611-617
36. Noguchi S, Motomura K, Inaji H, Imaoka S and Koyama H (1993) Down-regulation of transforming growth factor-α by tamoxifen in human breast cancer. Cancer 72: 131-136
37. Noonan KE, Beck C, Holzmayer TA, Chin JE, Wunder JS, Andrulis II, Gazdar AF, Willman CL, Griffith B, Von Hoff DD and Roninson IB (1990) Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by PCR. Proc Natl Acad Sci USA 87: 7160-7164
38. Nordeen SK (1988) Luciferase reporter gene vectors for analysis of promoters and enhancers. Bio Techniques 6: 454-457
39. Philips A, Chalbos D and Rochefort H (1993) Estradiol increases and anti-estrogens antagonize the growth factor-induced activator protein-1 activity in MCF-7 breast cancer cells without affecting c-fos and c-jun synthesis. J Biol 268: 14103-14108
40. Pink JJ and Jordan VC (1996) Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines. Cancer Res 56: 2321-2330
41. Saeki T, Cristiano A, Lynch MJ, Brattain M, Kim N, Normanno N, Kenney N, Ciardiello F and Salomon DS (1991) Regulation by estrogen through the 5′-flanking region of the transforming growth factor α gene. Mol Endocrinol 5: 1955-1963
42. Salomon DS, Kidwell WR, Kin N, Ciardiello F, Bates SE, Valverius EM, Lippman ME, Dickson RB and Stampfer MR (1989a) Modulation by estrogen and grow th factors of transforming growth factor α and epidermal growth factor receptor expression in normal and malignant human mammary epithelial cells. Recent Results Cancer Res 113: 57-69
43. Salomon DS, Ciardiello F, Valverius EM, Saeki T and Kim N (1989b) Transforming growth factors in human breast cancer. Biomed Pharmacother 43: 661-667
44. Smith CL, Nawaz Z and O'Malley BW (1997) Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol Endocrinol 11: 657-666
45. Sundstrom SA, Komm BS, Xu Q, Boundy V and Lyttle CR (1990) The stimulation of uterine complement component C3 gene expression by antiestrogens. Endocrinology 126: 1449-1456
46. Tahara M, Tasaka K, Masumoto N, Adachi K, Adachi H, Ikebuchi Y, Kurachi H and Miyake A (1995) Expression of messenger ribonucleic acid for epidermal growth factor (EGF), transforming growth factor-α (TGFα), and EGF receptor in human amnion cells: possible role of TGFα in prostaglandin E2 synthesis and cell proliferation. J Clin Endocrinol Metab 80: 138-146
47. Tonetti DA and Jordan VC (1995) Possible mechanisms in the emergence of tamoxifen-resistant breast cancer. Anti-Cancer Drugs 6: 498-507
48. Tonetti DA and Jordan VC (1996a) Design of an ideal hormone replacement therapy for women. Mol Carcinog 17: 108-111
49. Tonetti DA and Jordan VC (1996b) Targeted antiestrogens to treat and prevent diseases in women. Mol Med Today 2: 218-223
50. Umayahara Y, Kawamori R, Watada H, Imano E, Iwama N, Morishima T, Yamasaki Y, Kajimoto Y and Kamada T (1994) Estrogen regulation of the insulin-like growth factor I gene transcription involves AP-1 enhancer. J Biol Chem 269: 16433-16442
51. Wakeling AE and Bowler J (1988) Novel antiestrogens without partial agonist activity. J Steroid Biochem 31: 645-653
52. Wakeling AE, Dukes M and Bowler J (1991) A potent specific pure antiestrogen with clinical potential. Cancer Res 51: 3867-3873
53. Webb P, Lopez GN, Uht RM and Kushner PJ (1995) Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol Endocrinol 9: 443-156
54. Wolf DM and Jordan VC (1994a) Characterization of tamoxifen stimulated MCF-7 tumor variants grown in athymic mice. Breast Cancer Res Treat 31: 117-127
55. Wolf DM and Jordan VC (1994b) The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain. Breast Cancer Res Treat 31: 129-138
56. Yang NN, Venugopalan M, Hardikar S and Glasebrook A (1996) Identification of an estrogen response element activated by metabolites of 17β-estradiol and raloxifene. Science 273: 1222-1224